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bstract
A simple, sensitive, precise high-performance thin-layer chromatographic (HPTLC) method has been developed for estimat-
ng irbesartan and amlodipine besylate in combination. It involves TLC aluminium plates pre-coated with silica gel 60-F254
s the stationary phase and a solvent system of chloroform/toluene/methanol/acetic acid (6/2.5/1.5/0.5, v/v/v/v). The Rf values
ere 0.57 ±  0.02 for irbesartan and 0.30 ±  0.02 for amlodipine besylate. The separated spots were analysed densitometrically in
bsorbance mode at 244 nm. The results were linear in the range 50–500 ng per band for irbesartan and 400–900 ng per band for
mlodipine besylate, with limits of detection of 14.4 ng per band and 12.7 ng per band, respectively. The limits of quantification were
7.4 ng per band for irbesartan and 42.0 ng per band for amlodipine. After irbesartan and amlodipine stock solutions were subjected
o acid and alkaline hydrolysis, chemical oxidation, dry heat degradation and photodegradation, the peaks for degraded product
ere well resolved from that for pure drug, with significant differences in their Rf values when assayed by the HPTLC method. The
ethod was validated with respect to linearity, accuracy, precision and robustness and was used successfully to estimate irbesartan
nd amlodipine besylate in a synthetic mixture.
 2015 Taibah University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
http://creativecommons.org/licenses/by-nc-nd/3.0/).




4-one) has the empirical formula C25H28N6O and a
olecular mass of 428.5 g/mol (Fig. 1) [1]. Irbesartan
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of hypertension, as it selectively blocks the binding of
angiotensin II to the AT1 receptor, produces arteriolar
and venous dilatation and blocks aldosterone secretion,
thus lowering blood pressure and decreasing salt and
water retention [2].
Amlodipine besylate is chemically 3-ethyl,5-methyl
(4RS)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-
6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benz-
ene sulphonate with the empirical formula
C26H31ClN2O8S and a molecular mass of 567.1 g/mol
(Fig. 2) [1]. It is a long-acting (dihydropyridine class)
2+. This is an open access article under the CC BY-NC-ND license
Ca channel antagonist used as an anti-hypertensive and
in the treatment of angina. Like other calcium channel
blockers, amlodipine besylate protects tissues by inhibit-
ing the entrance of calcium into cardiac and smooth
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muscle cells of the coronary and systemic arterial beds.
It is therefore an arteriolar vasodilator that decreases
smooth muscle tone and vascular resistance [3].
A fixed-dose, single-pill combination is available,
in which the constituent drugs exert additive effects.
The fixed-dose combination has been associated with a
greater decrease in mean diastolic blood pressure when
seated at home and in mean systolic and diastolic blood
pressure when seated at the office than monotherapy
[4,5].
The International Conference on Harmonization
guideline on stability testing of new drug substances
and products requires that stress testing be carried out to
determine the stability of the active substance [6]. Sus-
ceptibility to oxidation is one of the required tests, and
hydrolytic and photolytic stability testing are required.
An ideal method for indicating stability is one that allows
quantification of the drug and resolution of its degrada-
tion products.
A literature survey on studies of the quantitative
analysis of these drugs showed analytical methods that
have been tested for estimating irbesartan alone and in
combination with other drugs by liquid chromatogra-
phy [6–9], high-performance thin-layer chromatography
(HPTLC) [10–12] and spectrophotometry [13–15]; spec-
trophotometric methods [16,17], HPLC [18,19] and
HPTLC [20,21] have been tested for estimating amlodip-
ine besylate alone and in combination with other drugs.
HPTLC has the advantage that many samples can be
analysed in a short time, and a new stationary plate can be
taken for analysis, which prevents the carry-over found
with HPLC. For routine quality control analysis, HPTLC
is therefore preferred to HPLC. No HPTLC method has
been reported for estimating the stability of irbesartan
and amlodipine besylate in combination.
Fig. 2. Chemical structure of AML.rsity for Science 9 (2015) 177–186
2.  Experimental
2.1.  Instruments
The HPTLC instrument consisted of a CAMAG
(Muttenz, Switzerland) Linomat V sample applica-
tor with a 100-L applicator syringe (Hamilton,
Bonadauz, Switzerland). Chromatography was per-
formed on 10 cm ×  10 cm aluminium TLC plates
precoated with silica gel 60-F254 (E. Merck, Darmstadt,
Germany; supplied by Anchrom Technologists, Mum-
bai, India). A CAMAG TLC scanner 4 was used for
densitometric scanning of the chromatogram. All drugs
and chemicals were weighed on a Shimadzu electronic
balance (AX 200, Shimadzu Corp., Japan).
2.2.  Chemicals  and  reagents
Analytically pure irbesartan (99.5%) and amlodipine
besylate (99.5%) were donated by CTX (Surat, India)
and Blue Cross Laboratory Ltd. (Mumbai, India), respec-
tively. Toluene was purchased from Chiti-Chem Corp.
(Baroda, India). Chloroform was obtained from Krishna-
chem-Industry (Baroda, India). Methanol was obtained
from Suvidinath Laboratory (Baroda, India) and acetic
acid from Chemdyes Corporation (Baroda, India).
2.3.  Chromatographic  system
2.3.1.  Sample  application
Standards and synthetic mixture samples of irbesar-
tan and amlodipine besylate were applied to the HPTLC
plates in the form of narrow bands 6 mm in length applied
10 mm from the bottom and 15 mm from the left edge
of the plate. Samples were applied under a continuous
drying stream of nitrogen gas.
2.3.2. Mobile  phase  and  development
Plates were developed in a mobile phase consisting of
chloroform/toluene/methanol/acetic acid (6/2.5/1.5/0.5,
v/v/v/v). Linear ascending development was carried out
in a twin-trough glass chamber equilibrated with the
mobile phase vapours for 15 min. Ten millilitres of the
mobile phase (5 mL in the trough containing the plate and
5 mL in the other trough) were used for each develop-
ment and were allowed to migrate a distance of 80 mm.
After development, the HPTLC plates were dried com-
pletely.2.3.3. Densitometric  analysis
Densitometric scanning was performed in the
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hromatography software (CAMAG, Muttenz,
witzerland). The source of radiation was a deu-
erium lamp, and bands were scanned at 244 nm. The
lit dimensions were 5 mm in length and 0.45 mm in
idth, with a scanning rate of 20 mm/s. Concentrations
f the compound were determined from the intensity
f diffusely reflected light and evaluated as peak areas
gainst concentrations from a linear regression equation.
.4.  Preparation  of  standard  stock  solution
Ten-milligram aliquots of standard irbesartan and
mlodipine besylate were accurately weighed, trans-
erred to two separate 10-mL volumetric flasks and
issolved in a few millilitres of methanol. The volumes
ere made up to the mark with methanol to yield a
olution containing 1000 g/mL. Aliquots of the stock
olutions were appropriately diluted with methanol to
btain working standards of 100 g/mL of both drugs.
.5.  Validation
The HPTLC method was validated according to the
nternational Conference on Harmonization guidelines
2 (R1) [22].
.5.1.  Linearity  of  calibration  curves
The linearity of the method was evaluated by con-
tructing calibration curves at five concentrations over
 range of 50–400 ng per band for irbesartan and
00–900 ng per band for amlodipine besylate. The cali-
ration curves were prepared by plotting peak area versus
oncentration (n  = 5).
.5.2. Accuracy
The accuracy of the method was determined by cal-
ulating the recoveries of the two drugs by standard
dditions. Known amounts of irbesartan (0, 160, 200
nd 240 ng per band) and amlodipine besylate (0, 324,
05 and 486 ng per band) were taken from the working
tandard solutions and were added to pre-quantified sam-
les. The amounts of drug were estimated by measuring
he areas and by fitting these values to the straight-line
quations of the calibration curves.
.5.3. Precision
Intra-day precision was determined by analysing sam-
le solutions of irbesartan (50, 300 and 500 ng per band)
nd amlodipine besylate (400, 700 and 900 ng per band)
hree times on the same day. Inter-day precision was
etermined by analysing sample solutions of irbesartan
50, 300 and 500 ng per band) and amlodipine besylatesity for Science 9 (2015) 177–186 179
(400, 700 and 900 ng per band) over 3 days. The peak
areas obtained were used to calculate mean and relative
standard deviation (% RSD).
The repeatability of measures of the peak area was
determined by analysing irbesartan (300 ng per spot) and
amlodipine besylate (700 ng per spot) seven times with-
out changing the position of the plate. The repeatability
of injection was checked by applying seven tracks of
irbesartan and amlodipine besylate on the same plate.
2.5.4. Speciﬁcity
Specificity was studied in forced degradation studies.
2.5.4.1. Alkaline  hydrolysis.  Appropriate aliquots of
stock solutions of irbesartan and amlodipine besylate
were taken in two 10-mL volumetric flasks, and 2 mL
of 0.1 N NaOH were added. The mixtures were heated
in a water bath at 80 ◦C for 1 h and allowed to cool to
room temperature. Solutions were neutralized with 0.1 N
HCl and diluted up to the mark with methanol.
2.5.4.2.  Acid  hydrolysis.  Appropriate aliquots of stock
solutions of the two drugs were taken in two 10-mL vol-
umetric flasks, and 2 mL of 0.1 N HCl were added. The
mixtures were heated in a water bath at 80 ◦C for 1 h
and allowed to cool to room temperature. Solutions were
neutralized with 0.1 N NaOH and diluted up to the mark
with methanol.
2.5.4.3.  Oxidative  stress  degradation.  Appropriate
aliquots of stock solutions of the two drugs were taken in
two 10-mL volumetric flasks, and 2 mL of 3% hydrogen
peroxide were added. The mixtures were heated in a
water bath at 80 ◦C for 1 h, allowed to cool to room
temperature and diluted up to the mark with methanol.
2.5.4.4. Dry  heat  degradation.  Analytically pure sam-
ples of irbesartan and amlodipine besylate were exposed
in an oven at 80 ◦C for 2 h. The solids were allowed to
cool, and 10 mg of each drug were weighed, transferred
to two 10-mL volumetric flasks and dissolved in a few
millilitres of methanol. Volumes were made up to the
mark with methanol.
2.5.4.5. Photodegradation.  Analytically pure samples
of irbesartan and amlodipine besylate were exposed to
ultraviolet light for 6 h. The solids were allowed to cool,
and 10 mg of each drug were weighed, transferred to two
10-mL volumetric flasks and dissolved in a few millil-
itres of methanol. Volumes were made up to the mark
with methanol.
 Unive180 D.A. Shah et al. / Journal of Taibah
All the reaction solutions were applied to TLC plates,
and chromatograms were recorded with the HPTLC
method.
2.5.5. Sensitivity
The limit of detection (LOD) is the lowest concentra-
tion of an analyte that can reliably be differentiated from
background levels. The limit of quantification (LOQ) of
an individual analytical procedure is the lowest amount
of analyte that can be quantitatively determined with
suitable precision and accuracy.
The LOD and LOQ were calculated from the follow-
ing equations as per the ICH guidelines:
LOD =  3.3 × σ
S
LOQ =  10 × σ
S
where σ  is the standard deviation of y  intercepts of regres-
sion lines, and S  is the slope of the calibration curve.
2.5.6. Robustness
The effects of small changes in the chamber saturation
time and solvent migration distance were examined. The
robustness of the method was determined in triplicate
at concentrations of 300 ng per band for irbesartan and
700 ng per band for amlodipine besylate.
2.5.7. Solution  stability
Solutions at analytical concentrations (irbesartan,
300 ng per band and amlodipine besylate, 700 ng per
band) were prepared and stored at room temperature
(25 ±  2 ◦C) for 24 h and analysed at intervals of 0, 6, 12
and 24 h for the presence of any band other than those of
the drugs. The results were compared with freshly pre-
pared standard solutions of the same concentrations and
expressed as changes in RSD.
2.6.  Analysis  of  synthetic  mixture
As the marketed formulation was under patent, it
was difficult to obtain, and a synthetic mixture was
prepared to determine the suitability of the method.
The synthetic mixture was prepared with the ingredi-
ents commonly used in tablet formulation: hypromellose
(2%), microcrystalline cellulose (28%), croscarmellose
sodium (4.8%), magnesium stearate (1%) and silicon
dioxide (1%) [23].
Synthetic powder equivalent to 100 mg irbesartan and
10 mg amlodipine besylate was taken in a 10-mL vol-
umetric flask, methanol was added, and the flask wasrsity for Science 9 (2015) 177–186
sonicated for 15 min. The solution was filtered through
Whatman filter paper No. 41, and the volume was made
up to the mark with methanol.
An appropriate volume of the aliquot was transferred
to a 10-mL volumetric flask, and the volume was made
up to the mark with methanol. This solution (100 g/mL
amlodipine besylate) was used to estimate amlodipine
besylate (700 ng per band). The solution was further
diluted with methanol to obtain 100 g/mL irbesartan
and used to estimate irbesartan (300 ng per band).
3.  Results  and  discussion
3.1.  Optimization  of  the  mobile  phase
To make the HPTLC method suitable for estimat-
ing irbesartan and amlodipine besylate in combined
dosage form, the mobile phase was selected on the
basis of polarity to give a dense, compact band
with an appropriate Rf value for the two drugs. Sat-
isfactory resolution of the drugs was not achieved
with mixtures of toluene/methanol (7/3, v/v), chlo-
roform/methanol (6/4, v/v), chloroform/toluene (8/2,
v/v), chloroform/acetonitrile (8/2, v/v), acetonitrile/ethyl
acetate (8/2, v/v) and chloroform/methanol/toluene
(6/3/1, v/v). Chloroform/toluene/methanol/acetic acid
(6/2.5/1.5/0.5, v/v/v/v) was found to be a satisfactory
mobile phase, giving good separation of irbesartan and
amlodipine besylate.
Chamber saturation time and solvent migration dis-
tance were crucial to chromatographic separation. A
chamber saturation time of less than 15 min and sol-
vent migration distances greater than 80 mm resulted
in diffusion of the analyte band. Therefore, chloro-
form/toluene/methanol/acetic acid as the mobile phase,
a chamber saturation time of 15 min under ambient
conditions and a solvent migration distance of 80 mm
were selected as the optimum conditions. These chro-
matographic conditions produced well-defined, compact
bands of irbesartan and amlodipine besylate with Rf
0.57 ±  0.02 and 0.30 ±  0.02, respectively (Fig. 3).
3.2.  Selection  of  detection  wavelength
The sensitivity of an HPTLC method with ultravio-
let detection depends on an appropriate wavelength. The
drug mixture in solution was applied in the form of a
band at concentrations of 50–500 ng per band of irbesar-
tan and 400–900 ng per band of amlodipine besylate in
methanol. The mixture was placed into the syringe and
applied under a nitrogen stream to a single plate, which
was developed with chloroform/toluene/methanol/acetic



























cid (6/2.5/1.5/0.5, v/v/v/v) under ambient conditions
nd dried in air. The developed plate was subjected
o densitometric measurements in scanning mode in
he ultraviolet region of 200–400 nm, and the overlaid
pectrum was recorded on a CAMAG TLC Scanner 4.
oth drugs absorbed appreciably at 244 nm, which was
elected as the detection wavelength (Fig. 4).
.3.  Validation
.3.1.  Linearity  and  calibration  curves
The linearity of an analytical method is its abil-
ty, within a given range, to provide results that are
irectly, or through a mathematical transformation, pro-
ortional to the concentration of the analyte. The method
as found to be linear in a concentration range of
0–500 ng per band for irbesartan and 400–900 ng per
and for amlodipine besylate. Regression data showed
 good linear relationship over the concentration range,
emonstrating the suitability of the method for analysis
Table 1). Fig. 5 shows a three-dimensional overlay of
he HPTLC densitograms for irbesartan and amlodipine
esylate, with calibration bands at 244 nm.
.3.2.  Accuracy
The accuracy of an analytical method is the closenessf the results to the true value (100%). In recovery stud-
es in which a known amount of standard was spiked
nto pre-analysed sample solutions the recovery was
8.9–103.11% for irbesartan and 99.29–102.30% for AML and IRB.
amlodipine besylate (Table 2). The values demonstrate
that the method is accurate.
3.3.3.  Precision
Intra-day precision is measured for an analytical pro-
cedure used within a laboratory over a short time by
the same operator with the same equipment, whereas
inter-day precision involves estimation of variations in
analysis when the method is used on different days. The
RSD values of the response were less than 2% and 3% for
intra-day and inter-day precision, respectively. Repeat-
ability of the scanning device and injection was studied
by applying and analysing irbesartan and amlodipine
besylate samples (300 and 700 ng per band) seven times.
The RSD values were less than 2% (Table 2), indicating
that the method is repeatable and reproducible.
3.3.4.  Limit  of  detection  and  limit  of  quantiﬁcation
Under the experimental conditions used, the smallest
amounts of drug that could be detected were 14.4 ng per
band for irbesartan and 12.7 ng per band for amlodipine
besylate. The LOQs were 47.4 ng per band for irbesartan
and 42.0 ng per band for amlodipine besylate (Table 2),
indicating that nanogram quantities of the drugs can be
estimated accurately and precisely.3.3.5. Forced  degradation  study
The chromatograms after base hydrolysis at 80 ◦C for
2 h showed degradation of irbesartan with a product peak
at an Rf value of 0.44 and degradation of amlodipine
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Fig. 4. Overlaid spectra o
Table 1
Results of regression analysis of calibration curve.
Parameter Irbesartan Amlodipine
besylate
Linearity (ng per band) 50–500 400–900
Correlation coefficient (r2) 0.996 0.994
Slope of regression 4.19 2.15
Standard deviation of slope 0.09 0.03
Intercept of regression 1148.6 330.7
Standard deviation of regression 19.88 9.05
Fig. 5. Three-dimensional overlay of HPTLf IRB and AML.
besylate with peaks at Rf 0.03, 0.17 and 0.23 (Fig. 6).
The degradation peaks were well resolved from those for
pure drug.
The chromatograms of acid-degraded samples
showed degradation products peaks at Rf 0.02, 0.03 and
0.09 for amlodipine besylate, which were well resolved
from the drug peak. Irbesartan was found to be stable to
acid hydrolysis (Fig. 7). After dry heat degradation, the
chromatogram showed peaks at Rf 0.38 for irbesartan
and 0.01 and 0.03 for amlodipine besylate (Fig. 8). The
C densitograms of calibration bands.
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Table 2
Validation parameters of HPTLC.
Parameter Irbesartan Amlodipine
besylate
Linearity (ng per band) 50–500 400–900
Retention factor 0.57 ± 0.02 0.03 ± 0.02
Detection limit (ng per band) 14.4 12.7
Quantification limit (ng per band) 47.4 42.0
Accuracy (%) 98.9–103.11 99.29–102.30
Precision (% relative standard deviation)
Intra-day (n = 3) 1.12–1.19 1.12–1.28
Inter-day (n = 3) 1.96–2.33 2.09–2.20
Instrument precision (% relative standard deviation)
Scanner (n = 7) 0.11 0.16









PFig. 6. Chromatogram of base (0
able 3
esults of analysis of forced degradation.
ondition Time (h) Recov
Irbesa
cid 0.1 M HCl, reference (80 ◦C) 1 105.54
ase 0.1 M NaOH, reference (80 ◦C) 1 33.28
xidative degradation 3% H2O2, reference (80 ◦C) 1 99.33
ry heat (80 ◦C) 2 85.17
hotolysis 6 98.50sity for Science 9 (2015) 177–186 183
chromatogram after photodegradation showed product
peaks at Rf 0.01 for amlodipine besylate, while irbe-
sartan was stable (Fig. 9). Both drugs were stable to
oxidative hydrolysis.
The degradation studies therefore indicated that irbe-
sartan is stable to acid hydrolysis and oxidative stress
but susceptible to base hydrolysis, dry heat degrada-
tion and photodegradation. Amlodipine is susceptible
to acid and alkaline hydrolysis, photodegradation and
dry heat degradation and stable to oxidative stress
degradation (Table 3). None of the stress conditions
affected determination of irbesartan and amlodipine
besylate.3.3.6. Robustness
RSD values less than 2% were obtained after intro-
duction of small changes to the parameters of the HPTLC
method, confirming its robustness.
.1 N NaOH) hydrolysis.




 69.25 Not detected −0.02, 0.03, 0.09
 20.17 0.45 0.03, 0.17, 0.23
 98.47 Not detected Not detected
 98.73 0.38 0.01, 0.03
 75.67 Not detected 0.01
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Fig. 7. Chromatogram of acid (0.1 N HCl) hydrolysis.
m of dFig. 8. Chromatogra
3.3.7.  Solution  stability
The stability of sample solutions was studied at ambi-
ent condition for 24 h. Both drugs were stable, with a
recovery of more than 97%.
3.4.  Analysis  of  synthetic  mixtureAs the marketed formulation is under patent, it was
difficult to obtain, and a synthetic mixture was prepared
to check the suitability of the method. The syntheticry heat degradation.
mixture was prepared from amlodipine besylate,
irbesartan and the excipients hypromellose (2%), micro-
crystalline cellulose (28%), croscarmellose sodium
(4.8%), magnesium stearate (1%) and silicon dioxide
(1%) [23]. Analysis of the synthetic mixture by the
proposed method gave a recovery of 100.06% (±0.76%)
for a labelled amount of 100 mg irbesartan and 98.97%
(±0.65%) for a labelled amount of 10 mg amlodipine
besylate. Single bands at Rf 0.56 ±  0.02 and 0.29 ±  0.02
were observed in the chromatograms for irbesartan and






















mlodipine besylate, and no interference from the excip-
ents was observed. As the method can be successfully
pplied for analysis of the synthetic mixture, it could be
sed to analyse the marketed tablet formulation.
.  Conclusion
The stability of the irbesartan and amlodipine besy-
ate combination indicates that the HPTLC method can
e used to estimate the drugs in mixtures. The method
as found to be simple, sensitive, accurate and precise.
tatistical analysis showed that the method is repeatable
nd selective for the analysis of irbesartan and amlodip-
ne besylate in combination, with no interference from
xcipients. The method was successfully used to deter-
ine the drugs in a synthetic mixture. The results also
ndicate the suitability of the method under conditions
f acid, base, dry heat, wet heat and photodegradation.
s the method separates the drugs from its degradation
roducts, it can be used to analyse stability samples.
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